GlassScriptPhysician profile
Shivani Dhir
NPI 1801580980
$13,932.67
in general payments reported to CMS, 2019-2025
31 companies · $7,131 in 2025
The $7,131 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $928 · 2024: $5,874 · 2025: $7,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,140 · Education: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,178.77 |
| Consulting Fee | $1,140.00 |
| Education | $613.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,948.61 | 2023-2025 | Bimzelx |
| Genzyme Corporation | $1,611.91 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,450.51 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,216.70 | 2023-2025 | |
| Dermavant Sciences, INC. | $953.02 | 2023-2024 | Vtama |
| Leo Pharma INC. | $919.38 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $916.21 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $608.41 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $584.73 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $542.45 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $508.65 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $421.06 | 2024-2025 | |
| Pfizer INC. | $327.05 | 2024-2025 | |
| Galderma Laboratories, L.P. | $317.87 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $253.40 | 2023-2025 | Otezla, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.68 | 2024-2025 | Cabtreo, Siliq, Jublia |
| Sanofi-Aventis U.S. LLC | $186.94 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $151.52 | 2024-2025 | Tremfya |
| Merz North America, INC. | $149.96 | 2025 | |
| Botanix Sb INC | $144.69 | 2025 | Sofdra |
| Takeda Pharmaceuticals U.S.A., INC. | $112.49 | 2025 | |
| Incyte Corporation | $103.02 | 2024-2025 | Opzelura |
| Organon LLC | $97.88 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.40 | 2023-2024 | Spevigo |
| Convatec INC. | $37.34 | 2024 | |
| Verrica Pharmaceuticals INC. | $27.27 | 2024 | Ycanth |
| Tempus Ai, INC | $22.58 | 2024 | Merlin Test |
| Surgenex LLC | $19.56 | 2025 | Surgraft, Ardeograft, Pellograft |
| Fresenius Kabi USA, LLC | $17.27 | 2024 | Idacio |
| Medtronic, INC. | $16.55 | 2024 | Venaseal |
| Genentech USA, INC. | $13.56 | 2023 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Dhir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.